AsymMirai: Interpretable Mammography-based Deep Learning Model for 1-5-year Breast Cancer Risk Prediction.

Radiology

From the Departments of Computer Science (J.D., L.M., A.J.B., C.R.) and Electrical and Computer Engineering (C.R.), Duke University, 308 Research Dr, LSRC Building D101, Duke Box 90129, Durham, NC 27708; Department of Radiology and Imaging Services, Emory University, Atlanta, Ga (H.T.); Department of Radiology, Harvard University, Cambridge, Mass (F.S.); and Department of Radiology, Duke University School of Medicine, Durham, NC (J.L.).

Published: March 2024

Background Mirai, a state-of-the-art deep learning-based algorithm for predicting short-term breast cancer risk, outperforms standard clinical risk models. However, Mirai is a black box, risking overreliance on the algorithm and incorrect diagnoses. Purpose To identify whether bilateral dissimilarity underpins Mirai's reasoning process; create a simplified, intelligible model, AsymMirai, using bilateral dissimilarity; and determine if AsymMirai may approximate Mirai's performance in 1-5-year breast cancer risk prediction. Materials and Methods This retrospective study involved mammograms obtained from patients in the EMory BrEast imaging Dataset, known as EMBED, from January 2013 to December 2020. To approximate 1-5-year breast cancer risk predictions from Mirai, another deep learning-based model, AsymMirai, was built with an interpretable module: local bilateral dissimilarity (localized differences between left and right breast tissue). Pearson correlation coefficients were computed between the risk scores of Mirai and those of AsymMirai. Subgroup analysis was performed in patients for whom AsymMirai's year-over-year reasoning was consistent. AsymMirai and Mirai risk scores were compared using the area under the receiver operating characteristic curve (AUC), and 95% CIs were calculated using the DeLong method. Results Screening mammograms ( = 210 067) from 81 824 patients (mean age, 59.4 years ± 11.4 [SD]) were included in the study. Deep learning-extracted bilateral dissimilarity produced similar risk scores to those of Mirai (1-year risk prediction, = 0.6832; 4-5-year prediction, = 0.6988) and achieved similar performance as Mirai. For AsymMirai, the 1-year breast cancer risk AUC was 0.79 (95% CI: 0.73, 0.85) (Mirai, 0.84; 95% CI: 0.79, 0.89; = .002), and the 5-year risk AUC was 0.66 (95% CI: 0.63, 0.69) (Mirai, 0.71; 95% CI: 0.68, 0.74; < .001). In a subgroup of 183 patients for whom AsymMirai repeatedly highlighted the same tissue over time, AsymMirai achieved a 3-year AUC of 0.92 (95% CI: 0.86, 0.97). Conclusion Localized bilateral dissimilarity, an imaging marker for breast cancer risk, approximated the predictive power of Mirai and was a key to Mirai's reasoning. © RSNA, 2024 See also the editorial by Freitas in this issue.

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.232780DOI Listing

Publication Analysis

Top Keywords

breast cancer
24
cancer risk
24
bilateral dissimilarity
20
1-5-year breast
12
risk
12
risk prediction
12
risk scores
12
mirai
10
asymmirai
9
breast
8

Similar Publications

Gene Polymorphisms in Greek Primary Breast Cancer Patients.

Front Biosci (Schol Ed)

December 2024

Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.

Background: Breast cancer is a heterogeneous disease with distinct clinical subtypes, categorized by hormone receptor status, which exhibits different prognoses and requires personalized treatment approaches. These subtypes included luminal A and luminal B, which have different prognoses. Breast cancer development and progression involve many factors, including interferon-gamma ().

View Article and Find Full Text PDF

Objective: The current study aimed to develop an experimental approach for the direct co-culture of three-dimensional breast cancer cells using single-cell RNA sequencing (scRNA-seq).

Methods: The following four cell culture groups were established in the Matrigel matrix: the untreated Michigan Cancer Foundation (MCF)-7 cell culture group, the MCF-7 cell culture plus cisplatin group, the untreated co-culture group, and the cell co-culture plus cisplatin group. For cell co-culture, MCF-7 cells, human mammary fibroblasts, and human umbilical vein endothelial cells were mixed at a ratio of 1:1:1.

View Article and Find Full Text PDF

Clinical Relevance and Drug Modulation of PPAR Signaling Pathway in Triple-Negative Breast Cancer: A Comprehensive Analysis.

PPAR Res

December 2024

Department of Laboratory Medicine, The Sixth School of Clinical Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.

Triple-negative breast cancer (TNBC) is highly heterogeneous and poses a significant medical challenge due to limited treatment options and poor outcomes. Peroxisome proliferator-activated receptors (PPARs) play a crucial role in regulating metabolism and cell fate. While the association between PPAR signal and human cancers has been a topic of concern, its specific relationship with TNBC remains unclear.

View Article and Find Full Text PDF

Previous studies have demonstrated that many healthcare workers in low- and middle-income countries (LMICs) lack the appropriate training and knowledge to recognize and diagnose breast cancer at an early stage. As a result, women in LMICs are frequently diagnosed with late-stage breast cancer (Stage III/IV) with a poor prognosis. We hosted a 1-day breast cancer educational conference directed towards healthcare workers in Honduras.

View Article and Find Full Text PDF

Deep learning identification of novel autophagic protein-protein interactions and experimental validation of Beclin 2-Ubiquilin 1 axis in triple-negative breast cancer.

Oncol Res

December 2024

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.

Background: Triple-negative breast cancer (TNBC), characterized by its lack of traditional hormone receptors and HER2, presents a significant challenge in oncology due to its poor response to conventional therapies. Autophagy is an important process for maintaining cellular homeostasis, and there are currently autophagy biomarkers that play an effective role in the clinical treatment of tumors. In contrast to targeting protein activity, intervention with protein-protein interaction (PPI) can avoid unrelated crosstalk and regulate the autophagy process with minimal interference pathways.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!